Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins

Brain Research Bulletin

Volumn 79, Issue 5, 2009, Pages 303-309

  Nagel, Florian ^a,b   Bähr, Mathias ^a,b   Dietz, Gunnar P H ^a,b,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DFG Research Center for the Molecular Physiology of the Brain CMPB   (Germany)

^c H LUNDBECK A S   (Denmark)

Author keywords

Cell penetrating peptide; Dopamine; MPTP; Neurodegeneration; Parkinson's disease; Retina model

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; OXIDOPAMINE; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERNEURON; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA AMACRINE CELL; TOXICITY TESTING;

AMACRINE CELLS; ANIMALS; ASTROCYTES; CELL DEATH; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; EYE; GLIOSIS; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; MPTP POISONING; NEURONS; OXIDOPAMINE; ROTENONE; TYROSINE 3-MONOOXYGENASE;

EID: 65749109505     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.04.010     Document Type: Article

References (43)

1. Adams J.D., Pickford M.S., and Wong C.G. The acute retinal histopathology of MPTP. Neurotoxicology 13 (1992) 541-549
2. Adler R. Determination of cellular types in the retina. Invest. Ophthalmol. Vis. Sci. 34 (1993) 1677-1682
3. Ambrosio S., Blesa R., Mintenig G.M., Palacios-Araus L., Mahy N., and Gual A. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina and caudate nucleus of the cat. Toxicol. Lett. 44 (1988) 1-6
4. Antal A., Pfeiffer R., and Bodis-Wolllner I. Simultaneously evoked primary and cognitive visual evoked potentials distinguish younger and older patients with Parkinson's disease. J. Neural. Transm. 103 (1996) 1053-1067
5. Azadi S., Johnson L.E., Paquet-Durand F., Perez M.T., Zhang Y., Ekstrom P.A., and van Veen T. CNTF + BDNF treatment and neuroprotective pathways in the rd1 mouse retina. Brain Res. 1129 (2007) 116-129
6. Bähr M. Live or let die-retinal ganglion cell death and survival during development and in the lesioned adult CNS. Trends Neurosci. 23 (2000) 483-490
7. Biehlmaier O., Alam M., and Schmidt W.J. A rat model of Parkinsonism shows depletion of dopamine in the retina. Neurochem. Int. 50 (2007) 189-195
8. Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism Relat. Disord. 9 (2003) S83-S89
9. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci. 13 (1990) 296-302
10. Bodis-Wollner I., and Tagliati M. The visual system in Parkinson's disease. Adv. Neurol. 60 (1993) 390-394
11. Cenni M.C., Bonfanti L., Martinou J.C., Ratto G.M., Strettoi E., and Maffei L. Long-term survival of retinal ganglion cells following optic nerve section in adult bcl-2 transgenic mice. Eur. J. Neurosci. 8 (1996) 1735-1745
12. Chen S.T., Hsu J.R., Hsu P.C., and Chuang J.I. The retina as a novel in vivo model for studying the role of molecules of the Bcl-2 family in relation to MPTP neurotoxicity. Neurochem. Res. 28 (2003) 805-814
13. Cheng Z., Zhong Y.M., and Yang X.L. Expression of the dopamine transporter in rat and bullfrog retinas. Neuroreport 17 (2006) 773-777
14. Cohen J.L., and Dowling J.E. The role of the retinal interplexiform cell: effects of 6-hydroxydopamine on the spatial properties of carp horizontal cells. Brain Res. 264 (1983) 307-310
15. Cronin T., Leveillard T., and Sahel J.A. Retinal degenerations: from cell signaling to cell therapy; pre-clinical and clinical issues. Curr. Gene Ther. 7 (2007) 121-129
16. Cuenca N., Herrero M.T., Angulo A., de Juan E., Martinez-Navarrete G.C., Lopez S., Barcia C., and Martin-Nieto J. Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson's disease. J. Comp. Neurol. 493 (2005) 261-273
17. Dietz G.P.H., Kilic E., and Bähr M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol. Cell Neurosci. 21 (2002) 29-37
18. Dietz G.P.H., Stockhausen K.V., Dietz B., Falkenburger B.H., Valbuena P., Opazo F., Lingor P., Meuer K., Weishaupt J.H., Schulz J.B., and Bähr M. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. J. Neurochem. 104 (2008) 757-765
19. Dietz G.P.H., Valbuena P.C., Dietz B., Meuer K., Mueller P., Weishaupt J.H., and Bähr M. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res. 1082 (2006) 61-66
20. Djamgoz M.B., Hankins M.W., Hirano J., and Archer S.N. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res. 37 (1997) 3509-3529
21. Dong Z., Wolfer D.P., Lipp H.P., and Bueler H. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol. Ther. 11 (2005) 80-88
22. Guarnieri T., Virgili M., Carraro S., and Villani L. Quinolinic acid but not MK-801 protects the dopaminergic system from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced toxicity in goldfish retina. Neurochem. Int. 24 (1994) 559-564
23. Harnois C., and Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest. Ophthalmol. Vis. Sci. 31 (1990) 2473-2475
24. Jackson-Lewis V., and Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2 (2007) 141-151
25. Klöcker N., Kermer P., Weishaupt J.H., Labes M., Ankerhold R., and Bähr M. Brain-derived neurotrophic factor-mediated neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3′-kinase/protein kinase B signaling. J. Neurosci. 20 (2000) 6962-6967
26. Lin Z.S., and Yazulla S. Depletion of retinal dopamine increases brightness perception in goldfish. Vis. Neurosci. 11 (1994) 683-693
27. Liss B., Haeckel O., Wildmann J., Miki T., Seino S., and Roeper J. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci. 8 (2005) 1742-1751
28. Nagel F., Falkenburger B.H., Tönges L., Kowsky S., Pöppelmeyer C., Schulz J.B., Bähr M., and Dietz G.P.H. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J. Neurochem. 105 (2008) 853-864
29. Nagel F., Dohm C.P., Bähr M., Wouters F.S., and Dietz G.P.H. Quantitative evaluation of chaperone activity and neuroprotection by different preparations of a cell-penetrating Hsp70. J. Neurosci. Methods 171 (2008) 226-232
30. Nguyen-Legros J., Harnois C., Di Paolo T., and Simon A. The retinal dopamine system in Parkinson's disease. Clin. Vis. Sci. 8 (1993) 1-12
31. Olivier P., Jolicoeur F.B., Lafond G., Drumheller A.L., and Brunette J.R. Dose related effects of 6-OHDA on rabbit retinal dopamine concentrations and ERG B-wave amplitudes. Brain Res. Bull. 16 (1986) 751-753
32. Przedborski S., Tieu K., Perier C., and Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J. Bioenerg. Biomembr. 36 (2004) 375-379
33. Qu Z.X., Neff N.H., and Hadjiconstantinou M. MPP+ depletes retinal dopamine and induces D-1 receptor supersensitivity. Eur. J. Pharmacol. 148 (1988) 453-455
34. Sagliocco L., Bandini F., Pierantozzi M., Mari Z., Tzelepi A., Ko C., Gulzar J., and Bodis-Wollner I. Electrophysiological evidence for visuocognitive dysfunction in younger non-Caucasian patients with Parkinson's disease. J. Neural. Transm. 104 (1997) 427-439
35. Schmidt W.J., and Alam M. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). J. Neural. Transm. Suppl. (2006) 273-276
36. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318 (2004) 215-224
37. Schulz J., and Beal M. Mitochondrial dysfunction in movement disorders. Curr. Opin. Neurol. 7 (1994) 333-339
38. Shevtsova Z., Malik I., Garrido M., Schöll U., Bähr M., and Kügler S. Potentiation of in vivo neuroprotection by BclX(L) and GDNF co-expression depends on post-lesion time in differentiated CNS neurons. Gene Ther. 13 (2006) 1569-1578
39. P. Sterling, Retina, in: G.M. Shepherd (Ed.), The Synaptic Organization of the Brain, Oxford University Press, New York, NJ, 1990, pp. 171-198 (Chapter 6).
40. Tatton W.G., Kwan M.M., Verrier M.C., Seniuk N.A., and Theriault E. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res. 527 (1990) 21-31
41. Villani L., Beraudi A., Giuliani A., and Poli A. MPTP-induced apoptosis in the retina of goldfish. Neurotox. Res. 3 (2001) 255-257
42. Xia X.G., Harding T., Weller M., Bieneman A., Uney J.B., and Schulz J.B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98 (2001) 10433-10438
43. Yazulla S., and Studholme K.M. Differential reinnervation of retinal bipolar cell dendrites and axon terminals by dopamine interplexiform cells following dopamine depletion with 6-OHDA. J. Comp. Neurol. 382 (1997) 535-545